

Proteome- and Transcriptome-wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia

Running title: *Ardissino & Truong et al.; Proteomic and transcriptomic study of preeclampsia*

Maddalena Ardissino, MSc^{1-4*}; Buu Truong, PhD^{5,6*}; Eric A.W. Slob, PhD⁷⁻¹⁰;
Art Schuermans^{5,6,11}; Satoshi Yoshiji, MD¹²; Alec P. Morley, BA^{13,14}; Stephen Burgess, PhD⁷;
Fu Siong Ng, MBBS³; Antonio de Marvao, MBBS¹⁵⁻¹⁷; Pradeep Natarajan, MD^{5,6};
Kypros Nicolaides, MD^{15,17}; Liam Gaziano, PhD^{1,18}; Adam Butterworth, PhD^{1,2,19-21};
Michael C. Honigberg, MD^{5,6,22}

¹British Heart Foundation Cardiovascular Epidemiology Unit, Dept of Public Health & Primary Care, ²Victor Phillip Dahdaleh Heart & Lung Rsrch Inst, ⁷MRC Biostatistics Unit, ¹³Dept of Medicine, School of Clinical Medicine, ¹⁴Gonville & Caius College, ¹⁹British Heart Foundation Ctr of Rsrch Excellence, ²⁰Health Data Rsrch UK Cambridge, Wellcome Genome Campus, ²¹National Inst for Health Rsrch Blood & Transplant Rsrch Unit in Donor Health & Genomics, Univ of Cambridge, Cambridge; ³National Heart and Lung Inst, ⁴Medical Rsrch Council, London Inst of Medical Sciences, Imperial College London, London, UK; ⁵Program in Medical and Population Genetics & Cardiovascular Disease Initiative, ¹²Programs in Metabolism and Medical & Population Genetics, Broad Inst of Harvard & MIT, Cambridge; ⁶Ctr for Genomic Medicine & Cardiovascular Rsrch Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ⁸Dept of Applied Economics, Erasmus School of Economics, ⁹Erasmus Univ Rotterdam Inst for Behavior and Biology, ¹⁰Dept of Psychology, Education & Child Studies, Erasmus Univ Rotterdam, Rotterdam, the Netherlands; ¹¹Faculty of Medicine, KU Leuven, Leuven, Belgium; ¹⁵Dept of Women & Children's Health, ¹⁶British Heart Foundation Ctr of Rsrch Excellence, School of Cardiovascular Medicine & Sciences, King's College London; ¹⁷Fetal Medicine Rsrch Inst, King's College Hospital, London, UK; ¹⁸Massachusetts Veterans Epidemiology Rsrch & Information Ctr (MAVERIC), VA Boston Healthcare System; ²²Dept of Medicine, Harvard Medical School, Boston, MA

*contributed equally

Correspondence:

Michael C Honigberg, MD, MPP

Massachusetts General Hospital

185 Cambridge St. CPZN 3.187

Boston, MA 02114

Tel: +1 617-726-1843

E-mail: mhonigberg@mgh.harvard.edu

Abstract

Background - Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. However, current understanding of its underlying biological pathways remains limited.

Methods - In this study, we performed a cross-platform proteome- and transcriptome-wide genetic analysis aimed at evaluating the causal relevance of more than 2,000 circulating proteins with preeclampsia, supported by data on expression of over 15,000 genes across 36 tissue leveraging large-scale preeclampsia genetic association data from women of European ancestry.

Results - We demonstrate genetic associations of 18 circulating proteins with preeclampsia (SULT1A1, SH2B3, SERPINE2, RGS18, PZP, NOTUM, METAP1, MANEA, jun-D, GDF15, FGL1, FGF5, FES, APOBR, ANP, ALDH-E2, ADAMTS13, 3MG), among which 11 were either directly or indirectly supported by gene expression data, 9 were supported by Bayesian colocalization analyses, and 5 (SERPINE2, PZP, FGF5, FES and ANP) were supported by all lines of evidence examined. Protein interaction mapping identified potential shared biological pathways through natriuretic peptide signalling, blood pressure regulation, immune tolerance and thrombin activity regulation.

Conclusions - This investigation identified multiple targetable proteins linked to cardiovascular, inflammatory, and coagulation pathways, with SERPINE2, PZP, FGF5, FES and ANP identified as a pivotal proteins with likely causal roles in the development of preeclampsia. The identification of these potential targets may guide the development of targeted therapies for preeclampsia.

Key words: preeclampsia, proteins, genes, Mendelian randomization, genetics, pathways

Nonstandard Abbreviations and Acronyms

MR = Mendelian randomization

GWAS = Genome wide association study

pQTL = protein quantitative trait loci

eQTL = expression quantitative trait loci

PPH1 = posterior probability of hypothesis 1

PPH2 = posterior probability of hypothesis 2

PPH3 = posterior probability of hypothesis 3

PPH4 = posterior probability of hypothesis 4

Introduction

Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. Current understanding of its underlying biological pathways remains limited. This is a great hindrance to the development of therapies which might prevent its development and downstream consequences on short- and long-term maternal and fetal health. To date, only a handful of drugs have been tested in randomized clinical trials to prevent preeclampsia, and only one therapy, aspirin, has demonstrated efficacy in high-risk women and been translated to clinical recommendations¹.

Proteins play a key role in human biology and are the primary targets of most drug therapies. Understanding the causal relevance of proteins and their networks on diseases can aid drug development and repurposing by uncovering the key underlying biological processes, providing rationale for intervening on these proteins with drugs. This can streamline the discovery process and increase the efficiency of drug development.

Mendelian randomization (MR) is a genetic epidemiological method that leverages the natural randomness that is involved in the inheritance of many risk factors, to inform the causal relevance of these risk factors on a specific disease². In the proteomic setting, the MR paradigm leverages the natural variability in genetic variants encoding proteins, which are potential drug targets, to explore the predicted effects of their perturbation. Since allocation of these genetic variants that determine circulating protein levels occurs randomly through the process of mating and allele assortment at conception, the method resembles randomisation in a clinical trial. In this way, it can be helpful in providing evidence to support causal relevance of a protein on a disease with less potential for issues relating to confounding and reverse causation. Additionally, it can help overcome the limitations of cell or mouse models that may not fully replicate human biological processes. It is therefore a valuable tool in drug discovery: therapies targeting proteins that are supported by evidence from human genetic studies have been shown to have a greater efficacy in trials and are more likely to gain regulatory approval³.

In recent years, there has been an increase in large-scale profiling of the plasma proteome and transcriptome. This has led to the creation of extensive catalogues of genetic variants that influence protein levels and gene transcription across hundreds of tissues within the human body. Combining these two resources allows for in-depth exploration of biological pathways underlying diseases, allowing the examination of the gene expression and downstream proteomic signatures that might influence disease outcomes with a causal role⁴.

In this study, we performed a proteome-wide genetic analysis aimed at evaluating the causal relevance of more than 1,500 circulating proteins for risk of preeclampsia across two different proteomic platforms, and corroborated and extended these analyses with data on expression of over 15,000 genes across 36 tissue types.

Methods

This study uses publicly available GWAS summary data accessible via the cited sources summarized in Table 1. All included studies had gained ethical approval and participant consent according to individual protocols available at the referenced publications. The study design is summarised in Figure 1, The methods for this study can be found in the Supplementary Methods.⁵⁻⁹

Results

Proteome-wide Mendelian randomization

After instrument selection and harmonization with outcome association data, pQTLs were available for analysis of 1,593 of the 1,881 proteins with *cis*-pQTLs in deCODE, and 1,991 of the 2,923 proteins in UK Biobank. There was no evidence of weak instruments, with all instruments exceeding the recommended F-statistic threshold of 10. All instrument F-statistics are presented in Supplementary Table 1.

Eighteen proteins had significant genetic associations with preeclampsia. Higher circulating levels of SULT1A1, SERPINE2, RGS18, NOTUM, METAP1, MANEA, FGL1, FES, APOBR, ANP, ADAMTS13 and 3MG were associated with lower risk of preeclampsia. Conversely, higher circulating levels of SH2B3, PZP, jun-D, GDF15, FGF5 and ALDH-E2 were associated with a greater risk of preeclampsia. The results are summarized in Figure 2, and presented in Supplementary Table 2 for deCODE and Supplementary Table 3 for UK Biobank. SERPINE2, PZP, and ADAMTS13 had available pQTLs and consistent associations with preeclampsia across both SOMAScan and Olink datasets.

Sensitivity analyses

Multiple sensitivity analyses were performed to address instrumental variable assumptions, the results of which are summarized in Table 2. Weighted median MR and MR-Egger were not possible for the primary pQTL instruments due to insufficient instruments at genome-wide significance level. After relaxing selection criteria for instruments ($p < 5 \times 10^{-6}$, $r^2 < 0.2$) and using MR-RAPS, the main analysis was replicated for all proteins except for SULT1A1, NOTUM, MANEA, jun-D, GDF15 (in both deCODE and UK Biobank) and ALDH-E2. After relaxing selection criteria for instruments, MR-Egger and weighted median MR produced consistent results for APOBR, FES, FGF5 and SERPINE2. Sensitivity analyses for ALDH-E2, FGL1, GDF15, MANEA, NOTUM and SULT1A1 were suggestive of horizontal pleiotropy either through a significant MR-Egger intercept (after accounting for multiple testing), or through inconsistency of results when utilising both MR-Egger and weighted median MR methods compared to the main results. The results suggested potential directional pleiotropy for 3MG, ADAMTS14, METAP1, and SH2B3, as the results were consistent on weighted median MR but not on MR-Egger, or vice versa. The analyses could not be performed for ANP, PZP, RGS18 because no additional SNPs were found with the relaxed criteria. The full results are outlined in Supplementary Table 4. Next, we performed a reverse direction MR analysis of significant pQTLs, which did not highlight any evidence of reverse causation (Supplementary Table 5). Finally, we repeated the analyses with a different data source, Zheng *et al.*'s study, for pQTL instruments⁴. In this data source, instruments for only 5 of the 18 pQTLs significant on primary analysis were available for validation. The results remained consistent for SERPINE2, PZP and GDF15, but not MANEA or FGL1 (Supplementary Table 6).

Colocalization

Using Bayesian colocalization analyses, we evaluated the posterior probability of shared causal variants within protein coding regions for the potentially causal pQTL with preeclampsia. The results are presented in Supplementary Table 7 and Supplementary Table 8 for deCODE and UK Biobank respectively.

In deCODE, results supported colocalization (PPH4 >80%) for SERPINE2 (99.7%), RGS18 (95.2%), PZP (89.8%), METAP1 (92.1%), jun-D (98.1%), ANP (88.4%), and 3MG (90.4%). In UKB, colocalization was supported for SERPINE2 (99.4%), PZP (89.9%), FGF5 (99.7%) and FES (87.9%). The results are presented in Figure 3. In total, 9 of the prioritized proteins were supported by colocalization in one or both datasets.

Transcriptome-wide Mendelian randomization

In the transcriptome-wide MR, we evaluated the association of gene expression for 103,476 gene/tissue combinations, spanning more than 15,000 genes across 36 different tissues with preeclampsia. Overall, 86 eQTLs displayed at least one association with preeclampsia in at least one tissue that was significant after adjustment for multiple comparisons. These are summarised in Supplementary Figure 1 and Supplementary Table 9.

Direct comparison with significant pQTL results

Comparing the eQTL results with those of the primary pQTL analysis, there was directionally consistent evidence corroborating the pQTL associations in at least one tissue for analysis for SULT1A1, SH2B3, SERPINE2, RGS18, FGF5, FES, ALDH-E2 and 3MG. Among these, ALDH2, FES, MANEA, RGS18, SERPINE2 and SULT1A1 were corroborated using whole blood eQTLs. No tissue-specific eQTL data was available for PZP, jun-D, FGL1, ANP and ADAMTS13. There was no evidence of a directionally consistent association for the remaining

pQTLs. Genetically predicted expression of METAP1 in aortic and tibial arterial tissue was significantly associated with preeclampsia, with opposing direction of effect compared to that observed for pQTLs.

Comparison with closely interacting proteins

In addition to looking for eQTL data that directly supports the pQTL findings, we expanded the comparison to also evaluate consistency of associations of eQTLs of the proteins with closest interactions to the significant pQTLs in the main analysis. These were identified as proteins with a STRING interaction score of more than 0.90, with a maximum of 5 proteins included for each significant pQTL. A summary of the identified proteins and the evidence supporting their interaction is provided in Supplementary Table 10.

In these analyses, biologically consistent associations of interacting proteins were noted for ANP, FGF5, SERPINE2, SH2B3 and SULT1A1. For ANP, the clearance receptor NPR3 eQTL was associated with preeclampsia in the opposite direction to the ANP pQTL, which is biologically consistent given its role in clearance of ANP, and a consistent association was found for NPR2 in the tibial artery. There were no additional findings for ADAMTS13, APOBR, FES, FGL1, GDF15, MANEA, METAP1, and RGS18, and no eQTLs relating to interacting proteins were available for 3MG and PZP. The results of the analyses are summarized in Figure 4.

Annotation

Protein function, interactions and druggability

The protein network displaying the 50 top high-confidence interactions (interaction score >0.70) for all 18 proteins is displayed in Supplementary Figure 2. A number of common STRING clusters were identified among the proteins, including ‘Complement and coagulation cascades, and Protein-lipid complex’ (ADAMTS13, APOBR, PZP), ‘Wnt signaling pathway’ (NOTUM,

ANP) and ‘Dissolution of Fibrin Clot’ (ADAMTS13, SERPINE2). Full functional annotation for all proteins is provided in Supplementary Table 11.

The results of the druggability evaluation for the significant pQTLs is presented in Supplementary Table 12. A total of 11 of the 18 proteins were classified as druggable (SERPINE2, PZP, NOTUM, METAP1, GDF15, FGL1, FGF5, ANP, ALDH-E2 and ADAMTS13). Among these, three are targets of currently available compounds (METAP1, ANP and ALDH-E2) of which none have safety data relating to pregnancy.

Phenome-wide scanning

The results of phenome-wide scanning for all significant pQTLs are shown in Supplementary Table 13. Among the 18 significant pQTLs, 10 had genome-wide significant associations with other traits. These included blood pressure and cardiovascular disease traits relating to coronary artery disease and heart failure (SH2B3, FGF5, FES, ANP, ALDH-E2), anthropometric traits relating to body mass index, size and adiposity (jun-D, GDF15, APOBR), blood cell traits (SH2B3, FGF5, jun-D, APOBR, ALDH-E2). Instruments for ADAMTS13 were only associated with ADAMTS13 levels in a separate study. FES was additionally associated with birth weight traits. Instruments for SERPINE2 were specifically only associated with platelet traits, as well as PDGF-BB levels, a clinical marker for preeclampsia¹⁰.

Discussion

In this study, we aimed to leverage large-scale genetic data to elucidate potential biological pathways contributing to the development of preeclampsia. Overall, genetically-predicted circulating levels of 18 proteins were associated with preeclampsia (SULT1A1, SH2B3, SERPINE2, RGS18, PZP, NOTUM, METAP1, MANEA, jun-D, GDF15, FGL1, FGF5, FES,

APOBR, ANP, ALDH-E2, ADAMTS13, 3MG). Among these, 11 were either directly or indirectly supported by gene expression data, and 9 were corroborated by colocalization analyses. Among the studied proteins, 5 were found to have consistent evidence of association and colocalization in all primary and sensitivity analysis (SERPINE2, PZP, FGF5, FES and ANP). Protein interaction mapping identified potential shared biological pathways through natriuretic peptide signalling, blood pressure regulation, immune tolerance and thrombin function.

In this study, lower genetically-predicted levels of SERPINE2 (i.e., serpin family E member 2), a serine protease that directly inhibits thrombin activity, was associated with preeclampsia. Though this association has not been identified before in observational research, the result was consistent across proteomic platforms, and was supported every sensitivity, eQTL and colocalization analysis. In addition, lower genetically-predicted levels of ADAMTS13, a disintegrin and metalloproteinase that modulates thrombin similarly to SERPINE2, were also associated with preeclampsia. Dysregulation of the thrombin pathway plays a well-recognised central role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a thrombotic microangiopathy with phenotypic overlap with preeclampsia¹¹. On the whole, these findings suggest deranged thrombin regulation as a key mechanism underlying the development of preeclampsia. This is consistent with the known clinical association between procoagulant conditions such as Factor V Leiden and preeclampsia risk¹², with the pathological overlap of preeclampsia with thrombotic microangiopathies¹³, and with the greater thrombin levels that women with preeclampsia display compared to controls¹⁴.

The role of ANP in the maintenance of cardiovascular homeostasis, regulation of natriuresis, vascular remodelling, and its interaction with the renin-angiotensin-aldosterone

pathway are well-described¹⁵⁻²¹. The role of ANP in the development of preeclampsia is less recognised but has been suggested in preclinical models. A previous study by Cui *et al.*²² demonstrated that pregnant mice lacking either ANP or corin (a cardiac protease that activates ANP, also known as ANP-converting enzyme) exhibited a preeclampsia phenotype. Observational studies have additionally demonstrated that low first trimester levels of the closely related NT-proBNP are associated with greater risk of hypertensive disorders of pregnancy²³, a finding corroborated by a recent protein-based MR study²⁴. In our study, lower genetically-predicted ANP levels were associated with preeclampsia. Then, when exploring the association of gene expression of ANP and its 5 strongest associated proteins with preeclampsia, we found that expression of NPR2, a receptor for both ANP and BNP, was associated with higher risk of preeclampsia, whereas greater expression of NPR3, a clearance receptor for ANP, is associated with greater risk of preeclampsia. Finally, colocalization analyses supported that the genetic predisposition to lower ANP and preeclampsia are due to a shared causal variant. On the whole, the combination of these findings support a causal relevance of low pre-pregnancy ANP levels in the development of preeclampsia that warrants its further investigation as a potential therapeutic target.

In the analysis in the UK Biobank, a strong genetic association was found between FGF5 (or fibroblast growth factor 5) and preeclampsia which was corroborated by colocalization. This was also corroborated by gene expression data, where renal cortex FGF5 expression was strongly associated with preeclampsia. FGF5 polymorphisms have been linked with preeclampsia in a Chinese population²⁵ and the FGF5 locus has been consistently prioritised as potentially causal in multiple GWASs of preeclampsia^{5,26,27} as well as blood pressure traits²⁸⁻³¹. Similarly, lower levels of FES, a protein regulating endothelial permeability and leukocyte transmigration, were

associated with preeclampsia across all analyses, indicating that *FES* is the likely causal gene at the previously identified *FURIN/FES* locus^{5,32}. Together with the additional association of *SH2B3*, another established blood pressure locus^{31,33-35}, this result supports the hypothesis that at least one of the mechanisms predisposing to preeclampsia is through a shared pathway with hypertension. This is in line with the multitude of observational evidence linking pre-existing hypertension to preeclampsia risk, and conversely, preeclampsia with later life hypertension risk³⁶. The present study extends these prior data by implicating renal physiology in preeclampsia risk and pinpointing an important role for *FGF5*.

The pathophysiological mechanism underpinning the associations of PZP with preeclampsia is unclear. Higher genetically-predicted levels of circulating maternal PZP were associated with higher risk of preeclampsia. PZP is a broad-spectrum immunosuppressive protein inhibits protease activity and stabilizes misfolded proteins, as well as modulating T helper cell response, through which it is thought to play a part in preventing rejection of the fetus during pregnancy³⁷. Its relevance in the pathophysiology of preeclampsia is not well studied to date, with only one study so far describing lower expression of PZP in preeclamptic placentas³⁸, an association which is opposite in direction to the findings of our study. This association suggests a potential importance of immune regulation and tolerance. Importantly, PZP has previously been highlighted as susceptibility loci in a previous GWAS study³². Overall, our study highlights a likely role of these two proteins in the development of preeclampsia that warrants further investigation.

In this study, we found that higher *GDF15* (or growth/differentiation factor 15) protein levels were associated with preeclampsia. *GDF15* is a protein that regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses, and has been

implicated as a key factor in the pathogenesis of hyperemesis gravidarum where high fetal protein levels are combined with maternal sensitivity to the hormone due to low intrinsic GDF15 levels³⁹. In the setting of preeclampsia, higher GDF15 levels have been described prior to diagnosis of preeclampsia⁴⁰, findings that were corroborated in a recent meta-analysis⁴¹. However, there was some inconsistency in sensitivity analyses in our study, and we were not able to corroborate this finding using gene expression data and in colocalization analyses. For this reason, its role in preeclampsia remains unclear and remains an important target for future investigation.

This study has a number of key strengths. First, the analysis spans a large scale of cross-platform proteomic and transcriptomic data, which has not been previously leveraged to investigate the biological pathways underlying preeclampsia. This higher coverage compared to any previous study increases the likelihood of uncovering important related mechanisms. In addition to this, we utilised a careful and step-wise approach starting with cross-platform proteomic data, corroborating it with transcriptomic data and colocalization analyses, and linking the results through interaction networks. This provides a comprehensive overview of the results and utilises available tools to help understand how the results of the analyses relate to each other. The use of MR and colocalization analyses helps increase confidence in the causal relevance of explored proteins on preeclampsia, where the results of these both support it. This is an important advantage, as it avoids the issues of confounding and reverse causation that often limit causal inference in biomarker studies of preeclampsia. Finally, the cross-platform approach is an important strength. Current data regarding the sensitivity and specificity of available commercial multiplexed protein assays is has highlighted important shortcomings⁴². For this reason, when proteome-wide exploration analyses are carried out, validation with both alternative proteomic

assays as well as gene expression data are crucial to lend reliability to the results and reassure against off-target results due to poor assay specificity.

Limitations

There are a number of limitations to discuss. First, despite using the largest-to-date studies available, protein and tissue-specific gene expression coverage in the data sources remain incomplete. For example, it can be noted that many of the proteins that have been observationally associated with preeclampsia (e.g., s-Flt1, PLGF, LEP, ENGL) were not available. In addition to this, no data were available for analysis of ANP in the replication analysis using Zheng *et al.*'s data⁴³, and similarly, there were no instruments for gene expression of the ANP gene, NPPA, in any of the studied tissues. Similar to this, even when instruments were available, where a result was not replicated in the transcriptome-wide MR its eQTL data was sometimes only available in very few tissues (e.g., GDF15, available in only one tissue). For this reason, a non-significant result might simply be due to lack of instrument availability in the 'correct' tissue where expression might relate to preeclampsia. Relating to this point, we were unable to analyse eQTL data for placental tissue. This is because, since the placenta is fetal and not maternal tissue, it is representative of fetal gene expression and would therefore require corresponding gene-outcome association data for fetal variants with maternal preeclampsia risk; as opposed to the gene-outcome association data used in this study that reflects the influence maternal variants on maternal preeclampsia risk. Second, in order to avoid potential confounding by population stratification, we restricted the analysis to using only data derived from European ancestry populations. This might limit the generalisability of the findings to populations of other ancestries. Given the lower risk of preeclampsia in women of European ancestry compared to, for example, those of African ancestry, it is imperative for this investigation to be repeated in

cohorts of other ancestries once sufficient data is available to do so. Finally, the reliability of MR results is strongly dependent on meeting instrumental variable assumptions. We addressed these in the study design by restriction of ancestry, utilisation of *cis*-MR to reduce risk of pleiotropy, as well as multiple sensitivity analyses and corroboration using gene expression data as well as colocalization. Nevertheless, even where robust evidence of potential causal relevance was found, validation of results in interventional trials remains the gold standard and cannot be replaced by genetic studies.

Conclusion

In this study, we performed a proteome- and transcriptome-wide genetic analysis aimed at evaluating the causal relevance of thousands of circulating proteins with preeclampsia, and supporting this with data on expression of over 15,000 genes across 36 tissue types. Our investigation identified multiple targetable proteins linked to cardiovascular, inflammatory, and coagulation pathways, with SERPINE2, PZP, FGF5, FES and ANP identified as a pivotal proteins with likely causal roles in the development of preeclampsia. Future studies should focus on evaluating an epidemiological temporal association of these proteins in women before and during pregnancy to corroborate the link with preeclampsia, and if this is confirmed, evaluate the efficacy and safety of intervening in these pathways through animal models and human trials.

Acknowledgments: The authors acknowledge all investigators and participants of the studies contributing to the present analyses.

Sources of Funding: This work was supported by core funding from the British Heart Foundation (RG/18/13/33946), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*], Cambridge BHF Centre of Research Excellence (RE/18/1/34212), BHF Chair Award (CH/12/2/29428). MA is supported by the National Institute for Health

Research Academic Clinical Fellowship. PN is supported by the U.S. National Heart, Lung, and Blood Institute (NHLBI R01HL127564, NHGRI U01HG011719). AdM is supported by the Fetal Medicine Foundation (495237). MCH is supported by the U.S. National Heart, Lung, and Blood Institute (NHLBI, K08HL166687) and the American Heart Association (940166, 979465). AB is supported by core funding from the British Heart Foundation (RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*]. All other authors have no funding to declare. *The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Disclosures: P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. MCH reports consulting fees from Comanche Biopharma, advisory board service for Miga Health, and grant support from Genentech, all unrelated to the present work. AB reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. All other authors have no disclosures to declare.

Supplemental Materials:

Supplemental Methods

Figures S1-S2

References 44-63

References:

1. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. *New England Journal of Medicine*. 2017;377:613-622. doi:10.1056/NEJMoa1704559

2. Burgess S, Scott RA, Timpson NJ, Smith GD, Thompson SG. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. *Eur J Epidemiol.* 2015;30:543-552. doi:10.1007/s10654-015-0011-z
3. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, et al. The support of human genetic evidence for approved drug indications. *Nat Genet.* 2015;47:856-860. doi:10.1038/ng.3314
4. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. *Nat Genet.* 2020;52:1122-1131. doi:10.1038/s41588-020-0682-6
5. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF, Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia and gestational hypertension. *Nat Med.* 2023;29:1540-1549. doi:10.1038/s41591-023-02374-9
6. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrnisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson B V., et al. Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet.* 2021;53:1712-1721. doi:10.1038/s41588-021-00978-w
7. Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, Surendran P, Mahajan A, Robins C, Vasquez-Grinnell SG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. *Nature.* 2023;622:329-338. doi:10.1038/s41586-023-06592-6
8. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet.* 2013;45:580-585. doi:10.1038/ng.2653
9. GTEx Consortium, Laboratory DA & Coordinating C (LDACC)—Analysis WG, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA, Biospecimen Collection Source Site—NDRI, et al. Genetic effects on gene expression across human tissues. *Nature.* 2017;550:204-213. doi:10.1038/nature24277
10. Liu M, Niu Y, Ma K, Leung PCK, Chen ZJ, Wei D, Li Y. Identification of novel first-trimester serum biomarkers for early prediction of preeclampsia. *J Transl Med.* 2023;21:634. doi:10.1186/s12967-023-04472-1
11. George JN, Nester CM, McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. *Hematology.* 2015;2015:644-648. doi:10.1182/asheducation-2015.1.644
12. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. *Am J Obstet Gynecol.* 1996;175:902-905. doi:10.1016/S0002-9378(96)80022-6

13. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. *Blood*. 2019;133:906-918. doi:10.1182/blood-2018-11-882993
14. Rafik Hamad R, Curvers J, Berntorp E, Eriksson MJ, Bremme K. Increased thrombin generation in women with a history of preeclampsia. *Thromb Res*. 2009;123:580-586. doi:10.1016/j.thromres.2008.03.022
15. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. *J Clin Invest*. 2012;122:1022-1036. doi:10.1172/JCI59701
16. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, Berlan M, Marques MA, Sweep FCGJ, Luft FC, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. *Diabetes*. 2008;57:3199-3204. doi:10.2337/db08-0649
17. Souza SC, Chau MDL, Yang Q, Gauthier MS, Clairmont KB, Wu Z, Gromada J, Dole WP. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. *Biochem Biophys Res Commun*. 2011;410:398-403. doi:10.1016/j.bbrc.2011.05.143
18. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. *J Am Coll Cardiol*. 2006;48:499-505. doi:10.1016/j.jacc.2005.12.081
19. Rubattu S, Marchitti S, Bianchi F, Di Castro S, Stanzione R, Cotugno M, Bozzao C, Sciarretta S, Volpe M. The C2238/ α ANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells. *PLoS One*. 2014;9:e113108. doi:10.1371/journal.pone.0113108
20. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel D V. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). *Science*. 1991;252:120-123. doi:10.1126/science.1672777
21. Lenz W, Herten M, Gerzer R, Drummer C. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. *Kidney Int*. 1999;55:91-99. doi:10.1046/j.1523-1755.1999.00242.x
22. Cui Y, Wang W, Dong N, Lou J, Srinivasan DK, Cheng W, Huang X, Liu M, Fang C, Peng J, et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. *Nature*. 2012;484:246-250. doi:10.1038/nature10897

23. Hauspurg A, Marsh DJ, McNeil RB, Bairey Merz CN, Greenland P, Straub AC, Rouse CE, Grobman WA, Pemberton VL, Silver RM, et al. Association of N-Terminal Pro-Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future Hypertension. *JAMA Cardiol.* 2022;7:268. doi:10.1001/jamacardio.2021.5617
24. Schuermans A, Truong B, Ardissino M, Bhukar R, Slob EAW, Nakao T, Dron JS, Small AM, Cho SMJ, Yu Z, et al. Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia. *JAMA Cardiol.* 2024;9:209-220. doi: 10.1001/jamacardio.2023.4994.
25. Xin Q, Han Y, Jiang W, Wang J, Luan Y, Ji Q, Sun W. Genetic susceptibility analysis of FGF5 polymorphism to preeclampsia in Chinese Han population. *Mol Genet Genomics.* 2022;297:791-800. doi:10.1007/s00438-022-01889-z
26. Steinhorsdottir V, McGinnis R, Williams NO, Stefansdottir L, Thorleifsson G, Shooter S, Fadista J, Sigurdsson JK, Auro KM, Berezina G, et al. Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. *Nat Commun.* 2020;11:5976. doi: 10.1038/s41467-020-19733-6.
27. Changelidis AI, Maksiutenko EM, Barbitoff YA, Tkachenko AA, Vashukova ES, Pachuliia O V, Nasykhova YA, Glotov AS. Aggregation of Genome-Wide Association Data from FinnGen and UK Biobank Replicates Multiple Risk Loci for Pregnancy Complications. *Genes (Basel).* 2022;13:2255. doi:10.3390/genes13122255
28. Takeuchi F, Akiyama M, Matoba N, Katsuya T, Nakatochi M, Tabara Y, Narita A, Saw WY, Moon S, Spracklen CN, et al. Interethnic analyses of blood pressure loci in populations of East Asian and European descent. *Nat Commun.* 2018;9:5052. doi:10.1038/s41467-018-07345-0
29. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C, Cook JP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet.* 2017;49:403-415. doi:10.1038/ng.3768
30. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, Shen H, He J, Zhu J, Li H, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Hum Mol Genet.* 2015;24:865-874. doi:10.1093/hmg/ddu478
31. Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, Kelly TN, Saleheen D, Lehne B, Leach IM, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat Genet.* 2015;4:1282-1293. doi:10.1038/ng.3405
32. Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S, Karjalainen J, Ripatti S, Kivioja A, Laisk T, et al. Genetic Risk Factors Associated With

Preeclampsia and Hypertensive Disorders of Pregnancy. *JAMA Cardiol.* 2023;8:674.
doi:10.1001/jamacardio.2023.1312

33. Feitosa MF, Kraja AT, Chasman DI, Sung YJ, Winkler TW, Ntalla I, Guo X, Franceschini N, Cheng CY, Sim X, et al. Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries. *PLoS One.* 2018;13:e0198166. doi:10.1371/journal.pone.0198166

34. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet.* 2009;41:677-687. doi:10.1038/ng.384

35. Alexander MR, Hank S, Dale BL, Himmel L, Zhong X, Smart CD, Fehrenbach DJ, Chen Y, Prabakaran N, Tirado B, et al. A Single Nucleotide Polymorphism in SH2B3/LNK Promotes Hypertension Development and Renal Damage. *Circ Res.* 2022;131:731-747.
doi:10.1161/CIRCRESAHA.121.320625

36. Ardissino M, Slob EAW, Millar O, Reddy RK, Lazzari L, Patel KHK, Ryan D, Johnson MR, Gill D, Ng FS. Maternal Hypertension Increases Risk of Preeclampsia and Low Fetal Birthweight: Genetic Evidence From a Mendelian Randomization Study. *Hypertension.* 2022;79:588-598. doi: 10.1161/HYPERTENSIONAHA.121.18617.

37. Skornicka EL, Kiyatkina N, Weber MC, Tykocinski ML, Koo PH. Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production. *Cell Immunol.* 2004;232:144-156. doi:10.1016/j.cellimm.2005.03.007

38. Löb S, Vattai A, Kuhn C, Mittelberger J, Herbert SL, Wöckel A, Schmoeckel E, Mahner S, Jeschke U. The Pregnancy Zone Protein (PZP) is significantly downregulated in the placenta of preeclampsia and HELLP syndrome patients. *J Reprod Immunol.* 2022;153:103663.
doi:10.1016/j.jri.2022.103663

39. Fejzo M, Rocha N, Cimino I, Lockhart SM, Petry CJ, Kay RG, Burling K, Barker P, George AL, Yasara N, et al. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. *Nature.* 2024;625:760-767. doi: 10.1038/s41586-023-06921-9.

40. Cruickshank T, MacDonald TM, Walker SP, Keenan E, Dane K, Middleton A, Kyritsis V, Myers J, Cluver C, Hastie R, et al. Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. *J Am Heart Assoc.* 2021;10:e020302. doi: 10.1161/JAHA.120.020302.

41. Wang L, Yang Q. Circulating Growth Differentiation Factor 15 and Preeclampsia: A Meta-Analysis. *Horm Metab Res.* 2023;55:114-123. doi: 10.1055/a-1956-2961.

42. Katz DH, Robbins JM, Deng S, Tahir UA, Bick AG, Pampana A, Yu Z, Ngo D, Benson MD, Chen ZZ, et al. Proteomic profiling platforms head to head: Leveraging genetics and clinical

- traits to compare aptamer- and antibody-based methods. *Sci Adv.* 2022;8:eabm5164. doi: 10.1126/sciadv.abm5164.
43. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. *Nat Genet.* 2020;52:1122-1131. doi:10.1038/s41588-020-0682-6
44. R Core Team. R: A language and environment for statistical computing. Computing. 2021;R Foundati.
45. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife.* 2018;7:e34408. doi: 10.7554/eLife.34408.
46. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol.* 2017;46:1734-1739. doi:10.1093/ije/dyx034
47. Haslam DE, Li J, Dillon ST, Gu X, Cao Y, Zeleznik OA, Sasamoto N, Zhang X, Eliassen AH, Liang L, et al. Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms. *Proteomics.* 2022;22:e2100170. doi: 10.1002/pmic.202100170.
48. Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, Janjic N. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. *Mol Ther Nucleic Acids.* 2014;3:e201. doi:10.1038/mtna.2014.49
49. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Res.* 2011;39:e102-e102. doi:10.1093/nar/gkr424
50. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015;44:512-525. doi:10.1093/ije/dyv080
51. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol.* 2016;40:304-314. doi:10.1002/gepi.21965
52. Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *The Annals of Statistics.* 2020;48. doi:10.1214/19-AOS1866

53. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, et al. Genomic atlas of the human plasma proteome. *Nature*. 2018;558:73-79. doi:10.1038/s41586-018-0175-2
54. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, Sarwath H, Thareja G, Wahl A, DeLisle RK, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. *Nat Commun*. 2017;8:14357. doi:10.1038/ncomms14357
55. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, Hoover H, Gudmundsdottir V, Horman SR, Aspelund T, et al. Co-regulatory networks of human serum proteins link genetics to disease. *Science*. 2018;361:769-773. doi:10.1126/science.aag1327
56. Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, Sun BB, Laser A, Maranville JC, Wu H, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. *Nat Commun*. 2018;9:3268. doi:10.1038/s41467-018-05512-x
57. Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Frånberg M, Sennblad B, Baldassarre D, Veglia F, Humphries SE, Rauramaa R, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. Ripatti S, ed. *PLoS Genet*. 2017;13:e1006706. doi:10.1371/journal.pgen.1006706
58. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLoS Genet*. 2014;10. doi:10.1371/journal.pgen.1004383
59. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, Wallace C, Burgess S. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. *Am J Hum Genet*. 2022;109:767-782. doi:10.1016/j.ajhg.2022.04.001
60. Ochoa D, Hercules A, Carmona M, Suveges D, Baker J, Malangone C, Lopez I, Miranda A, Cruz-Castillo C, Fumis L, et al. The next-generation Open Targets Platform: reimaged, redesigned, rebuilt. *Nucleic Acids Res*. 2023;51:D1353-D1359. doi:10.1093/nar/gkac1046
61. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. *Nucleic Acids Res*. 2015;43:D447-D452. doi:10.1093/nar/gku1003
62. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, Karlsson A, Santos R, et al. The druggable genome and support for target identification and validation in drug development. *Sci Transl Med*. 2017;9. doi:10.1126/scitranslmed.aag1166
63. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. 2019;35:4851-4853. doi:10.1093/bioinformatics/btz469

Table 1. Details of data sources utilised in this study

Phenotype	Data source	Number of participants	Data link
Preeclampsia	Honigberg <i>et al.</i> (2023) ⁵	16,349 cases / 595,135 controls	https://doi.org/10.6084/m9.figshare.22680904.v1
pQTLs	Ferkingstad <i>et al.</i> (2021) ⁶ deCODE	35,559	https://www.decode.com/summarydata/
	Sun <i>et al.</i> (2023) ⁷ UK Biobank	34,557	https://www.synapse.org/#!/Synapse:syn53038826/tables/
eQTLs	GTEEx Analysis Release V8 ^{8,9} (dbGaP Accession phs000424.v8.p2)	15,201 tissue samples from 838 donors	https://www.gtexportal.org/home/

Table 2. Summary of proteome-wide, transcriptome-wide and Bayesian genetic colocalization analysis for the proteins significant in the main analysis

Protein	Location (GrCh38)	Observational association (PMID)	Consistent in both deCODE and UKB	Consistent on MR-RAPS	Evidence of horizontal pleiotropy	No evidence of bidirectional association	Consistent in Zheng et al pQTLs	Supporting eQTL evidence	Interacting protein eQTL evidence	Colocalization supported
SULT1A1	16:28,605,196 - 28,614,279	29059671	Unavailable	No	Yes	Yes	Unavailable	Yes	Yes	No
SH2B3	12:111,405,923 - 111,451,623	33239696	Unavailable	Yes	Some	Yes	Unavailable	No	Yes	No
SERPINE2	2:223,975,045 - 224,039,318	-	Yes	Yes	None	Yes	Yes	Yes	Yes	Yes
RGS18	1:192,158,462 - 192,185,815	-	Unavailable	Yes	Unavailable	Yes	Unavailable	Yes	Yes	Yes
PZP	12:9,148,840 - 9,208,395	37285119; 35843132	Yes	Yes	Unavailable	Yes	Yes	Unavailable	Unavailable	Yes
NOTUM	17:81,952,507 - 81,961,840	-	Unavailable	No	Yes	Yes	Unavailable	No	Yes	No
METAP1	4:98,995,659 - 99,062,809	-	Unavailable	Yes	Some	Yes	Unavailable	No	No	Yes
MANEA	6:95,577,485 - 95,609,470	-	Unavailable	No	Yes	Yes	No	Yes	Yes	No
jun-D	19:18,279,694 - 18,281,622	24885447	Unavailable	No	Unavailable	Yes	Unavailable	Unavailable	Unavailable	Yes
GDF15	19:18,374,731 - 18,389,176	36410395	No	No	Yes	Yes	Yes	No	No	No
FGL1	8:17,864,380 - 17,910,365	36203334	Unavailable	Yes	Yes	Yes	No	No	No	No
FGF5	4:80,266,639 - 80,336,680	35380267; 33239696	Unavailable	Yes	None	Yes	Unavailable	Yes	Yes	Yes
FES	15:90,883,695 - 90,895,776	-	Unavailable	Yes	None	Yes	Unavailable	Yes	Yes	Yes
APOBR	16:28,494,643 - 28,498,964	-	Unavailable	Yes	None	Yes	Unavailable	Unavailable	No	No
ANP	1:11,845,709 - 11,848,345	15511835; 37248299	Unavailable	Yes	Unavailable	Yes	Unavailable	Unavailable	Yes	Yes
ALDH-E2	12:111,766,887 - 111,817,532	-	Unavailable	No	Yes	Yes	Unavailable	Yes	Yes	No
ADAMTS13	9:133,414,358 - 133,459,402	21512165	Yes	Yes	Some	Yes	Unavailable	Unavailable	No	No
3MG	16:77,007 - 85,851	-	Unavailable	Yes	Some	Yes	Unavailable	Yes	Yes	No

Figure Legends:


Figure 1. Flowchart outlining project design and statistical analysis. pQTLs = protein quantitative trait loci, EUR = European

Figure 2. Genetic associations of protein levels with preeclampsia, displaying all proteins associated with preeclampsia after correction for multiple testing in the main analysis. Grey fields indicate data was not available for analysis. PPH4 = Posterior probability of shared causal variant, PPH3 = Posterior probability of distinct causal variant. * = nominally significant ($p < 0.05$) ** = $p < 0.001$, *** = significant after Benjamini-Hochberg correction for multiple testing

Figure 3. Bayesian colocalization analysis evaluating the posterior probability of a shared causal variants influencing protein levels and preeclampsia risk, and probability of colocalization versus non-colocalization conditional on there being a causal variant for both traits [$PPH4 / (PPH3 + PPH4)$]. Grey fields indicate data was not available for analysis


Figure 4. Genetic associations of gene expression levels with preeclampsia, limited to the proteins identified as significant on the proteome-wide analysis or their closest interacting proteins (maximum of 5 proteins, all with STRING interaction score > 0.90). Grey fields indicate data was not available for analysis. * = nominally significant ($p < 0.05$) ** = $p < 0.001$, *** = significant after Benjamini-Hochberg correction for multiple testing


Proteome-wide Mendelian randomization




- Colocalization
- Sensitivity analyses
- Functional annotation and protein interaction networks
- Druggability
- Phenome-wide scan

Transcriptome-wide Mendelian randomization









Direction of association: Positive (Green), Negative (Orange), No significant association (Blue), Missing (Grey)